Ocugen Secures $7.1 Million Licensing Deal for Gene Therapy

Ocugen

MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has signed an exclusive licensing agreement worth up to $7.1 million in upfront and milestone payments with Australia’s Celairis Therapeutics Holdings Pty Ltd., expanding the potential commercial market for its experimental blindness gene therapy OCU400 across Australia, New Zealand and Southeast Asia.

The agreement gives Sydney-based Celairis exclusive commercialization rights to OCU400 in Australia, New Zealand and member countries of the Association of Southeast Asian Nations, a region with an estimated population of 725 million.

Ocugen will receive an upfront licensing fee and potential development and milestone payments totaling up to $7.1 million. Of that amount, $6.1 million is associated with the upfront payment and anticipated topline results from OCU400’s Phase 3 clinical trial, expected in the first quarter of 2027.

The agreement also provides Ocugen with a high-single-digit percentage royalty on net sales and 50% of gross profits from OCU400 net sales throughout the licensed territory.

READ:  Bentley Raises Revenue Growth Outlook as AI Demand Accelerates

The financial structure gives Ocugen potential near-term payments tied to clinical development while preserving a share of future commercial revenue if the treatment receives regulatory approval.

Celairis will manage regulatory submissions, market access and commercialization across the region. The companies also expect to enter a separate supply agreement under which Ocugen would manufacture and provide OCU400.

The partnership represents Ocugen’s third regional commercialization agreement for OCU400 as the Malvern-based biotechnology company prepares for potential regulatory submissions in major pharmaceutical markets.

OCU400 is an investigational modifier gene therapy being developed to treat retinitis pigmentosa, a group of inherited retinal disorders that progressively damage vision and can lead to blindness.

The treatment is designed as a potential one-time gene therapy, although its safety and effectiveness remain under clinical evaluation.

READ:  Bentley Expands Subsurface Software Business With Eliis Deal

Ocugen is conducting the Phase 3 liMeliGhT trial, with topline results expected during the first quarter of 2027. Those findings are expected to inform the company’s plans for regulatory applications in the United States and Europe.

The company intends to pursue a Biologics License Application with the U.S. Food and Drug Administration and a Marketing Authorization Application in Europe, followed by regulatory submissions in the territories covered by the Celairis agreement.

OCU400 has not received regulatory approval or registration in the licensed markets and is not currently available for commercial supply there.

“Australia, New Zealand, and ASEAN are large, diverse and complex markets, and establishing a partnership with a regional company like Celairis and its strong local network is critical to our goal of global patient access,” said Shankar Musunuri, Ocugen’s chairman, chief executive officer and co-founder.

READ:  PENN Entertainment Cuts Debt as Casino Revenue Hits Record

The arrangement allows Ocugen to rely on Celairis’ regional regulatory and commercialization capabilities rather than establish its own market-access operations across the participating countries.

Celairis specializes in licensing, developing and commercializing biopharmaceutical products in Australia, New Zealand, Taiwan and Southeast Asia.

“Celairis brings the development, regulatory, and market access capability to do that across our region,” said Matt Zeller, the company’s chief executive officer, co-founder and managing director.

The licensing agreement expands Ocugen’s potential international revenue opportunities ahead of a pivotal clinical milestone, with the timing of commercialization dependent on trial results and subsequent regulatory approvals.

Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.